Node.js released updates fixing a critical DoS flaw caused by async_hooks stack crashes, tracked as CVE-2025-59466, impacting ...

This video breaks down the bizarre legal battle over who owns the JavaScript name. Despite not creating or maintaining the language, Oracle controls the trademark. The story traces how this happened ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Google is apparently having trouble identifying paywalled content due to a standard way paywalled content is handled by publishers like news sites. It’s asking that publishers with paywalled content ...

Google has added new guidance to the "Fix Search-related JavaScript problems" help document, specifically addressing JavaScript-based paywalls. This is currently listed as number 10 here, and says: If ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

I now rate Recursion Pharma a sell due to disappointing recent trial updates and uncertain future prospects. REC-4881's phase 2 TUPELO trial showed mixed results, with one patient experiencing a ...